Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chinese Academy of Medical Sciences, People's Republic of China
Biomarkers for G-actin and DNA5cER may help distinguish malignant vs. benign breast disease
August 18th, 2006
Biomarkers for G-actin and DNA5cER may be useful to help distinguish malignant vs. benign breast disease. According to investigators at the Chinese Academy of Medical Sciences, "Recent studies show that morphology based analysis of ductal lavage specimens failed to detect many cancers in women with breast cancer. Such an observation raises doubts about the potential role of ductal lavage in an individual's risk assessment and early detection of breast cancer." W. Zhang and colleagues wrote, "We hypothesize that biomarker-based analysis using markers of malignancy field defects including DNA 5c exceeding rate (DNA 5cER) and G-actin might provide a...
Source: Biotech Law Weekly (2006-08-18)
|
